CARsgen's Satri-cel Perioperative Gastric/GEJ Consolidation: Zero Recurrences So Far in CT041-CG4010, ESMO 2026 Poster

Published: July 17, 2026 · Source: CARsgen Therapeutics Holdings Limited (2171.HK) press release, July 15, 2026 (Shanghai) · ESMO Congress 2026 abstract publication schedule · CT041-CG4010 / NCT06857786 ClinicalTrials.gov registration

CARsgen Therapeutics announced on July 15, 2026 that the preliminary investigator-initiated trial (IIT) results of satricabtagene autoleucel (satri-cel, CT041) as consolidation therapy following adjuvant treatment for locally advanced gastric or gastroesophageal junction (GEJ) cancer — the CT041-CG4010 trial, NCT06857786 — have been accepted as a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The press release states that "since the initiation of patient enrollment in May 2025 for the CT041-CG4010 trial, up to the date of this press release, none of the participants receiving satri-cel have experienced postoperative recurrence or metastasis of gastric cancer." The ESMO abstract will publish on October 19, 2026. For the substantial cohort of international patients with gastric or GEJ cancer who travel to Chinese tertiary cancer centers — from Indonesia, Vietnam, the Philippines, Russia, Kazakhstan, Saudi Arabia, and the UAE — the announcement extends the satri-cel story from a 3L+ commercial label (NMPA-approved June 22, 2026 for Claudin18.2-positive, HER2-negative advanced disease) into the much larger perioperative setting, where the eligible patient population is several-fold larger and the cure-rate stakes are far higher.

What CT041-CG4010 is testing

CT041-CG4010 is an investigator-initiated trial (IIT) running in China, registered on ClinicalTrials.gov as NCT06857786. The design is a perioperative consolidation study: patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who have undergone curative-intent surgical resection and completed standard adjuvant chemotherapy (typically a fluoropyrimidine plus oxaliplatin, or a FLOT-style triplet) are enrolled to receive satri-cel as consolidation therapy — an additional immunotherapy layer delivered after the standard adjuvant regimen is complete, with the goal of eradicating micrometastatic residual disease that would otherwise drive recurrence.

The key clinical question CT041-CG4010 is designed to answer is straightforward and consequential: in a population at high risk of recurrence after surgery plus standard adjuvant chemotherapy, does adding a Claudin18.2-directed CAR-T as consolidation reduce recurrence and improve long-term cure rates? This is the same clinical question that has driven the development of adjuvant and consolidation immunotherapy in other solid tumors (notably melanoma, where adjuvant pembrolizumab and adjuvant nivolumab are now standard after surgical resection) — but in a tumor type, gastric/GEJ cancer, where adjuvant immunotherapy has historically been less effective than in melanoma or even in lung cancer.

The clinical rationale for using a CAR-T rather than a checkpoint inhibitor in this consolidation setting is the depth and durability of the immune response. Checkpoint inhibitors work by reactivating existing tumor-reactive T cells; CAR-T provides an entirely new population of tumor-reactive T cells engineered ex vivo and infused back into the patient. The mechanistic hypothesis is that a CAR-T consolidation could clear Claudin18.2-positive micrometastatic deposits that a checkpoint inhibitor would miss, particularly in the adjuvant setting where tumor burden is low but the immune microenvironment is often tolerogenic.

Patient enrollment began in May 2025, so the trial has been running for approximately 14 months as of the July 15, 2026 press release. The CARsgen press release does not specify the total enrolled patient count at this interim point — that number will be in the ESMO abstract on October 19, 2026. The statement that "none of the participants receiving satri-cel have experienced postoperative recurrence or metastasis of gastric cancer" is a binary observation across all enrolled participants to date; it does not include a denominator, a follow-up duration, a confidence interval, or a comparison to a control arm (the trial is single-arm, so historical or contemporary controls are the natural comparison). These details are the substance of the ESMO presentation.

What "no recurrence so far" means at this stage

It is worth being careful about what the July 15 announcement does and does not tell us. The phrase "none of the participants receiving satri-cel have experienced postoperative recurrence or metastasis" is a safety-and-feasibility observation, not an efficacy readout in the registrational sense. Recurrence-free survival in a perioperative consolidation cohort is exactly the right endpoint to look at, but the readout requires both adequate follow-up and adequate patient numbers before any meaningful inference can be drawn.

Three limitations deserve flagging up front. First, follow-up duration is short. For perioperative gastric/GEJ cancer, the median time to recurrence after surgery and adjuvant chemotherapy is 18–36 months depending on stage and pathology. A median follow-up of 12–14 months in CT041-CG4010 (consistent with the May 2025 enrollment start and a July 2026 cutoff) would still be in the early-recurrence window, and the absence of events so far does not yet rule out late recurrences. Second, the patient count is small. Investigator-initiated trials in this setting typically enroll in cohorts of 10–40 patients at the interim look; without a denominator, the absence-of-events observation has limited statistical power. Third, there is no concurrent control arm — the natural comparison is historical cohorts of similar-stage patients receiving surgery plus adjuvant chemotherapy alone, where 3-year recurrence-free survival runs in the 50–65 percent range for stage III disease.

Within those limitations, the directional signal is the right direction. Zero recurrences across an entire enrolled cohort, with non-trivial follow-up, in a disease where recurrence is the norm rather than the exception, is an observation that justifies the ESMO poster acceptance and the continued enrollment. The October 19, 2026 abstract will tell us whether the signal is robust enough to support a registration-track trial in the same population, or whether the observation is a small-cohort early-look that needs more patients and longer follow-up.

For international patients watching the satri-cel story, the practical implication of the announcement is not that satri-cel is now an option for perioperative use — it has been an option on the CT041-CG4010 trial since May 2025 — but that the evidence base for that option has just become visible to the global oncology community. The ESMO acceptance itself is a marker of clinical interest, and the ESMO presentation in October 2026 will be the first time the full data are disclosed.

The perioperative angle in context: how CT041-CG4010 fits into satri-cel's expansion strategy

CT041-CG4010 is one of three active earlier-line satri-cel trials, and the three together describe CARsgen's commercial strategy for moving the drug up the treatment algorithm.

The commercial logic is sequential: establish the 3L+ indication first (which CARsgen did with the June 22, 2026 NMPA approval), then file for label expansion as the earlier-line data mature. Each earlier-line use case potentially multiplies the addressable patient population by an order of magnitude. The 3L+ setting covers patients who have failed two prior lines — a narrow population after second-line failure. The perioperative consolidation setting covers the much larger population of patients with locally advanced disease who have undergone curative-intent surgery — typically stage II or III disease with high-risk pathology features (lymph node involvement, lymphovascular invasion, poor differentiation). If the perioperative data hold, satri-cel moves from a late-line salvage therapy into the curative-intent pathway, where the clinical stakes (cure vs no cure) and the patient volume are both far higher.

For gastric cancer specifically, the perioperative setting is one of the most active clinical-investigation frontiers in oncology. The current standard for locally advanced resectable gastric/GEJ cancer is perioperative or adjuvant chemotherapy — FLOT in Western practice, XELOX or SOX in East Asian practice — which delivers a 5-year overall survival rate of approximately 45–55 percent for stage III disease. Adding a PD-1 inhibitor (pembrolizumab or nivolumab) to perioperative chemotherapy has lifted pathologic complete response rates in recent Phase III trials (KEYNOTE-585, MATTERHORN), but the survival benefit has been modest and is still maturing. The clinical question for satri-cel is whether a Claudin18.2-directed CAR-T can deliver a deeper immune response than a checkpoint inhibitor and translate into a larger survival gain.

What international patients should know about accessing satri-cel in mid-2026

Two pathways to satri-cel exist for international patients as of mid-2026, and the choice between them depends on the patient's clinical setting.

Pathway 1: Commercial access under the NMPA 3L+ label

Patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior systemic lines are commercially eligible for satri-cel at NMPA-licensed Chinese tertiary cancer centers. The list of treating centers has grown since the June 22, 2026 approval, but the early-adopter sites include Fudan University Shanghai Cancer Center, Peking University Cancer Hospital (Prof Lin Shen's group, which led the CT041-ST-01 registration trial), Sun Yat-sen University Cancer Center in Guangzhou, and several other tertiary centers in Shanghai, Beijing, and Guangzhou. International patient offices at these centers have established workflows for self-pay international patients, including apheresis scheduling, manufacturing slot booking, English-language coordination, and ICU-capable post-infusion monitoring.

Cost ranges for commercial satri-cel access in China are in the $89,000 to $151,000 USD range as published 2026 estimates for the product alone, with all-in package costs (apheresis, manufacturing slot, infusion, ICU-capable monitoring, 30–90 day post-infusion follow-up, English-language case management) typically $120,000 to $170,000 USD. This compares to $300,000 to $500,000 USD for the US CAR-T products approved for liquid tumors (Kymriah, Yescarta, Tecartus, Breyanzi), and there is no US-approved CAR-T for solid tumors as of mid-2026. Singapore, India, and Thailand do not have satri-cel commercially available. Hong Kong has access on a named-patient basis through certain hospital pharmacies, with logistics handled by the importing hospital.

Pathway 2: Trial access for earlier-line use

Patients who are not yet at the 3L+ stage — that is, patients with locally advanced disease who have had surgery but not yet failed two systemic lines, or patients in the first-line metastatic setting who have not yet exhausted standard options — can apply for trial access. CT041-CG4010 (NCT06857786) is the relevant trial for the perioperative consolidation scenario; NCT05911217 covers the pancreatic adjuvant scenario; NCT07179484 covers the 1L sequential gastric scenario. All three are open at Chinese tertiary centers, and international patient access is typically arranged through the center's international patient office or through an experienced medical concierge firm with established trial-site relationships.

The trial pathway typically requires the patient to meet eligibility criteria specific to each trial (stage, prior therapy, biomarker status, performance status, organ function), to be able to travel to the trial site for the apheresis / manufacturing / infusion sequence plus the required follow-up visits, and to self-pay the standard-of-care components (chemotherapy, hospital fees, monitoring) while the sponsor covers the satri-cel product itself. Total out-of-pocket cost for trial access is substantially lower than commercial access — typically in the $30,000 to $80,000 USD range across the full perioperative sequence, depending on the trial, the center, and the length of stay required.

Biomarker testing: where to start

For both pathways, biomarker testing is the first step. Claudin18.2 status must be confirmed by immunohistochemistry (IHC) on tumor tissue, with the standard cutoff used in the CT041-ST-01 registration trial being at least moderate-to-strong staining in at least 40 percent of tumor cells (the exact IHC scoring system and threshold vary by pathologist and by companion diagnostic assay). HER2 status must be negative (IHC 0 or 1+, or 2+ with FISH-negative). Most Chinese tertiary cancer centers run Claudin18.2 IHC in-house; if a patient's tissue is at an outside lab, the international patient office can usually arrange for slides or blocks to be sent for central review.

For patients whose tumors are Claudin18.2-negative, satri-cel is not an option. Other Claudin18.2-directed therapies (zolbetuximab, an antibody approved in 2024 for first-line use in the US; emerging CAR-T and ADC programs) have different biomarker thresholds and patient selection criteria, and may still be options. The international patient office at the treating center can guide the biomarker workup and the resulting clinical-pathway decision.

What to watch over the next 12–18 months

Three concrete readouts and milestones will shape the satri-cel story over the next 12–18 months and will directly affect international patient access.

First, the ESMO 2026 abstract on October 19, 2026. The full CT041-CG4010 dataset — patient count, follow-up duration, Claudin18.2 expression cutoffs, recurrence-free survival curve, any sub-group signals — will be disclosed at the ESMO Congress 2026 poster session. The size of the signal in the abstract will determine whether CARsgen moves toward a registration-track trial in the perioperative consolidation setting. International patients who are weighing whether to enroll in CT041-CG4010 versus wait for more data should monitor the ESMO presentation closely.

Second, the pancreatic adjuvant trial (NCT05911217) Phase 1 readout. Satri-cel is also being tested as adjuvant therapy in resected pancreatic adenocarcinoma — a setting where Claudin18.2 is expressed in a substantial fraction of pancreatic ductal adenocarcinomas and where standard adjuvant chemotherapy has a high recurrence rate. A positive Phase 1 readout from NCT05911217 would broaden satri-cel's reach well beyond gastric/GEJ cancer and would open a parallel access pathway for international patients with resected pancreatic cancer.

Third, the 1L sequential gastric trial (NCT07179484) interim data. This trial tests satri-cel after first-line chemotherapy in patients who have not yet progressed — a setting where earlier CAR-T intervention, when tumor burden is lower and immune function is more intact, could produce deeper and longer remissions than the third-line setting where the registration data were generated. An interim readout from NCT07179484 over the next 12–18 months would be the first direct evidence on whether earlier-line satri-cel outperforms the 3L+ benchmark.

For readers planning medical travel to China for gastric or GEJ cancer treatment, the practical access to satri-cel is already established for the 3L+ commercial setting and for the perioperative trial setting through CT041-CG4010. The October 19, 2026 ESMO abstract will tell the field how strongly the consolidation signal holds. The decisions that matter for the individual patient are the Claudin18.2 biomarker confirmation, the disease setting (3L+ advanced vs locally advanced post-surgery vs first-line metastatic), and the choice between commercial and trial access. These are the questions to bring to a Chinese tertiary cancer center MDT consultation; the rest of the satri-cel story will play out at ESMO 2026, the parallel earlier-line trials, and any subsequent NMPA label expansion filings over the next 24–36 months.